A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

NCT05648448

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Oxford
Enrollment	3,000 participants

Key Eligibility Criteria

Inclusion (6)

- Patient understands the procedures and requirements and is willing and able to give informed consent for full participation in the study
- Adults, male or female, aged 18 to 60 years at time of consent.
- Early symptomatic Influenza (A or B); at least one reported symptom of influenza (including fever, history of fever, myalgias, headache, cough, fatigue, nasal congestion, rhinorrhoea and sore throat) within 4 days (96 hours)
- Influenza positive by rapid antigen test OR a positive RT-PCR test for influenza viruses within the last 24hrs with a Ct value of \<30
- Able to walk unaided and unimpeded in activities of daily living (ADLs)

... and 1 more (see full listing online)

Exclusion (16)

- The patient may not enter the study if ANY of the following apply:
- Taking any concomitant medications or drugs which could interact with the study medications or have antiviral activity
- Presence of any chronic illness/condition requiring long term treatment or other significant comorbidity
- BMI e35 Kg/m2
- Clinically relevant laboratory abnormalities discovered at screening

... and 11 more (see full listing online)

Locations (4 total)

Universidade Federal de Minas Gerais, Minas Gerais, Brazil
Laos-Oxford-Mahosot Wellcome Trust Research unit, Vientiane, Laos
Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
... and 1 more locations